Via press release:
Health and Human Services Secretary Alex M. Azar II announced today that, as a result of discussions between the Trump Administration and Gilead Sciences, Inc., the pharmaceutical company has agreed to donate pre-exposure prophylaxis (PrEP) medication for up to 200,000 individuals each year for up to 11 years. PrEP is used to reduce the risk of HIV infection in individuals who are at higher risk for HIV. It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently.
The agreement between the U.S. Department of Health and Human Services and Gilead will last until at least December 31, 2025 and possibly through December 31, 2030, and will provide medication to treat individuals who are at risk for HIV and who are uninsured.
This donation will deliver Gilead’s PrEP medication Truvada, which currently carries a list price of more than $20,000 per patient per year, to up to 200,000 people per year, including in the states and counties identified as priority areas in the Trump Administration plan to end the HIV epidemic in America.
Gilead will donate Truvada until its second-generation HIV preventative medication, Descovy, becomes available. At that time, Gilead will donate Descovy. The agreement would end after 11 years, or when a generic version of Descovy becomes commercially available, whichever comes first. The government has agreed to cover costs associated with distributing the drugs
This is undeniably fantastic news. But the backstory is a bit more complicated than this press release reveals.
Great news today: My Administration just secured a historic donation of HIV prevention drugs from Gilead to help expand access to PrEP for the uninsured and those at risk. Will help us achieve our goal of ending the HIV epidemic in America! https://t.co/wux5QasWgW
— Donald J. Trump (@realDonaldTrump) May 9, 2019
— Adam W Gaffney (@awgaffney) May 9, 2019
Very exciting news! After @PrEP4AllNow's pressure, Gilead has agreed to release its exclusive patent the manufacturing and sale of Truvada as PrEP, meaning a generic is coming to the market soon. Here is our statement: https://t.co/WBMqfAqZve pic.twitter.com/nNXRUGL0R4
— Robert Kessler (@robertkessler) May 8, 2019